RxDoctor Payments Data

Nirmala Aryal, MD

Neurology · Phoenix, AZNPI 1306817572

Payments from drug & device makers

$13,304in general payments, 2019–2025

Across 816 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$1K
  • Biogen$1K
  • Teva Pharmaceuticals USA, Inc.$901
  • Acadia Pharmaceuticals Inc$684
  • Amneal Pharmaceuticals LLC$614
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$140%
  • Food & beverage$12,95897%
  • Education$3322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)187$2,224
UCB, Inc.101$1,433
Biogen56$1,037
Teva Pharmaceuticals USA, Inc.44$901
Acadia Pharmaceuticals Inc42$684
Amneal Pharmaceuticals LLC34$614
AstraZeneca18$601
Lilly USA, LLC32$539
Pfizer26$414
Upsher-smith Laboratories LLC22$365
Neurocrine Biosciences, Inc.16$325
Supernus Pharmaceuticals, Inc.32$303
Aucta Pharmaceuticals, Inc.16$299
Eisai Inc.13$282
Otsuka America Pharmaceutical, Inc.11$256
Bristol Myers Squibb13$231
Sanofi14$231
Novartis14$208
Amgen11$196
Genentech USA, Inc.8$172
Sunovion Pharmaceuticals Inc.10$165
SK Life Science, Inc.8$156
Johnson & Johnson1$140
Neurelis, Inc.7$134
Aprecia Pharmaceuticals, LLC5$88
Sumitomo Pharma America, Inc.6$81
Banner Life Sciences, LLC4$77
Kyowa Kirin, Inc.4$74
TG Therapeutics, Inc.3$68
Argenx US, Inc.4$67
Ipsen Biopharmaceuticals, Inc2$65
Lundbeck LLC4$65
Biohaven Pharmaceuticals, Inc.4$59
Impel Pharmaceuticals Inc.4$57
Livanova USA, Inc.3$52
Tanabe Pharma America, Inc.3$50
Harmony Biosciences LLC2$45
Corium, LLC4$42
Almatica Pharma LLC3$42
Arbor Pharmaceuticals, Inc.3$41
MDD US Operations, LLC1$32
Takeda Pharmaceuticals U.S.A., Inc.1$31
Impel Pharmaceuticals LLC1$29
Collegium Pharmaceutical, Inc.2$28
GE HealthCare1$28
Promius Pharma LLC2$27
EMD Serono, Inc.1$25
Merz Pharmaceuticals, LLC1$25
Xeris Pharmaceuticals, Inc.1$23
Biohaven Pharmaceutical Holding Company Ltd.1$20
Endo Pharmaceuticals Inc.1$19
Vertical Pharmaceuticals, LLC1$19
E.r. Squibb & Sons, L.L.C.1$19
Alfasigma USA, Inc.1$17
Vanda Pharmaceuticals Inc.1$14
Vertiflex, Inc.1$14
Catalyst Pharmaceuticals, Inc.1$14
Acorda Therapeutics, Inc1$14
ANI Pharmaceuticals, Inc.1$14
Currax Pharmaceuticals LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,304 in reported general payments places this provider in the 60th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$143,023
Medicare patients
315
Services billed
1,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant23$29,502
BotoxOnabotulinumtoxina27$28,760
QuliptaAtogepant21$26,776
NamzaricMemantine Hcl/Donepezil Hcl27$25,085
RexultiBrexpiprazole12$20,485
RytaryCarbidopa/Levodopa16$19,558
BriviactBrivaracetam12$16,139
Oxtellar XrOxcarbazepine17$12,580
Memantine Hcl ErMemantine Hcl86$7,376
Lacosamide60$7,353
Levetiracetam263$6,548
Rasagiline Mesylate27$5,482
Memantine Hcl161$4,248
Gabapentin417$3,993
Duloxetine Hcl142$2,782

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Botox, Qulipta, Namzaric$2,224$110,12298 claims
Otsuka America Pharmaceutical, Inc.Rexulti$256$20,48512 claims
Amneal Pharmaceuticals LLCRytary$614$19,55816 claims
UCB, Inc.Briviact$1,433$16,13912 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$303$12,58017 claims
Upsher-smith Laboratories LLCTopiramate$365$1,449103 claims
PfizerDilantin$414$49411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 388 neurology providers in Arizona.

Other neurology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →